{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:04:22Z","timestamp":1765667062285},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cjca.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T13:00:29Z","timestamp":1377262829000},"page":"1334-1345","source":"Crossref","is-referenced-by-count":69,"title":["Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Jean-Fran\u00e7ois","family":"Tanguay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L.","family":"Ackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.C.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee-Shian","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Douketis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Roussin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.07.001_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cjca.2010.12.015","article-title":"The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines","volume":"27","author":"Bell","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.07.001_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib4","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib5","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/eurheartj\/ehn417","article-title":"Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study","volume":"30","author":"Jolly","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.07.001_bib8","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.07.001_bib11","series-title":"Product monograph for Effient","author":"Eli Lilly Canada Inc","year":"2011"},{"key":"10.1016\/j.cjca.2013.07.001_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjcard.2011.05.020","article-title":"Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies","volume":"108","author":"Wiviott","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ahj.2010.10.017","article-title":"A\u00a0comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study","volume":"161","author":"Montalescot","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib15","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circualtion"},{"key":"10.1016\/j.cjca.2013.07.001_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib19","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"Storey","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib21","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.109.919001","article-title":"Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)","volume":"3","author":"Tsai","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.07.001_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jcin.2011.06.017","article-title":"Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents","volume":"4","author":"Kandzari","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.07.001_bib25","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1253\/circj.CJ-10-0347","article-title":"Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry","volume":"74","author":"Hahn","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2013.07.001_bib26","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198207083070201","article-title":"A\u00a0platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency","volume":"307","author":"Chesebro","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib28","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1161\/01.CIR.0000138790.14877.7D","volume":"110","author":"Eagle","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib29","doi-asserted-by":"crossref","first-page":"776S","DOI":"10.1378\/chest.08-0685","article-title":"The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Becker","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2013.07.001_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/1010-7940(93)90155-5","article-title":"Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis","volume":"7","author":"Fremes","year":"1993","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cjca.2013.07.001_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejcts.2005.11.033","article-title":"Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study","volume":"29","author":"Gurbuz","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cjca.2013.07.001_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.athoracsur.2009.04.024","article-title":"Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting","volume":"88","author":"Gao","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cjca.2013.07.001_bib33","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1161\/CIRCULATIONAHA.110.978007","article-title":"Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogel after surgery for coronary artery disease (CASCADE) trial","volume":"122","author":"Kulik","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib34","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.ahj.2010.07.035","article-title":"Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study","volume":"160","author":"Sun","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0828-282X(09)70527-6","article-title":"Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society","volume":"25","author":"Fitchett","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib37","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"228","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.07.001_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib40","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0735-1097(00)00521-0","article-title":"Catastrophic outcomes of noncardiac surgery soon after coronary stenting","volume":"35","author":"Kaluza","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","article-title":"Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group","volume":"29","author":"Lindahl","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib44","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.jacc.2011.02.009","volume":"57","author":"Wright","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skane","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cjca.2012.06.012","article-title":"Risk of bleeding on triple antithrombotic therapy following percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cjca.2012.08.008","article-title":"Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation","volume":"29","author":"Ho","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cjca.2012.08.014","article-title":"Trifecta or triple threat? The challenge of post-PCI management in patients receiving chronic oral anticoagulant therapy","volume":"29","author":"Healey","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.07.001_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46)","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.07.001_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib51","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary ayndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib53","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.07.001_bib54","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjca.2013.07.001_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/11584750-000000000-00000","article-title":"Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis","volume":"34","author":"Kwok","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2013.07.001_bib56","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A\u00a0population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2013.07.001_bib58","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/ajg.2010.334","article-title":"Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study","volume":"105","author":"van Boxel","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2013.07.001_bib59","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"11","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.07.001_bib61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2796.2011.02423.x","article-title":"Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial","volume":"271","author":"Burkard","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"Simon","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2036.2011.04890.x","article-title":"Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation","volume":"35","author":"Schmidt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.07.001_bib64","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.07.001_bib65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","article-title":"Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study","volume":"153","author":"Charlot","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.07.001_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/CIRCINTERVENTIONS.110.958884","article-title":"Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators","volume":"4","author":"Harjai","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.07.001_bib67","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.07.001_bib68","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2010.11.056","article-title":"Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis","volume":"140","author":"Hsu","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cjca.2013.07.001_bib69","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s10620-011-2007-1","article-title":"Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature","volume":"57","author":"Gerson","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cjca.2013.07.001_bib70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.arcmed.2012.04.004","article-title":"Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis","volume":"43","author":"Huang","year":"2012","journal-title":"Arch Med Res"},{"key":"10.1016\/j.cjca.2013.07.001_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13004431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13004431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T19:50:48Z","timestamp":1539460248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X13004431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0828282X13004431"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.07.001","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}